MKI67 and pancreatic neuroendocrine tumor: Chemotherapy was deemed indicated in patients with a possible chance of achieving a response, thereby enabling surgery.63 In pancreatic NETs, there was not a clear Ki-67 cut-off value found for recommending chemotherapy, but generally speaking, a Ki-67 cut-off value between 5% and 20% was considered acceptable.11 In addition, published case studies involving pancreatic NET patients for whom RLT was prescribed reported promising results obtained with neoadjuvant treatment administered for subsequent surgery.92,93